Madagascar vs Peru: Average cost of multi drug-resistant tuberculosis treatment
Madagascar
532 constant 2022 US$
in 2024
Peru
570 constant 2022 US$
in 2024
Madagascar rank
77th
Peru rank
75th
Average cost of multi drug-resistant tuberculosis treatment over time
- Madagascar
- Peru
How they compare
Peru currently reports 570 constant 2022 US$ against 532 constant 2022 US$ in Madagascar, a difference of 38 constant 2022 US$.
That makes Peru's figure about 1.1 times Madagascar's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Peru ahead.
Madagascar ranks 77th and Peru ranks 75th of 92 countries.
Across the 2 decades both report, Madagascar averaged higher in 1 and Peru in 1.
Head to head by decade
| Decade | Madagascar | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,509 constant 2022 US$ | 1,408 constant 2022 US$ | 100.67 constant 2022 US$ | Madagascar |
| 2020s | 622.2 constant 2022 US$ | 1,327 constant 2022 US$ | 704.8 constant 2022 US$ | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Madagascar or Peru?
- Peru, at 570 constant 2022 US$ against 532 constant 2022 US$ in Madagascar as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Madagascar and Peru?
- 38 constant 2022 US$, with Peru ahead.
- How many years of comparable data are there for Madagascar and Peru?
- 8 years are reported by both, from 2017 to 2024.
- How do Madagascar and Peru rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Madagascar ranks 77th and Peru ranks 75th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.